Documents

Displaying 41 - 60 of 91 results
 
Collapse Filters
 
Expand Filters         +
March 30, 2018

Chapter 78: Hazardous Waste and Chemical Storage

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 77: Safety

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 76: Laboratory Special Studies

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 75: Laboratory Financial and Resource Management

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 74: Managing Laboratory Stockpiles and Special Programs

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 73: Managing Laboratory Evidence

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 72: Staffing, Training, and Personnel Actions

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 71: Quality Assurance

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Chapter 70: Laboratory Operations

This document is an internal Drug Enforcement Administration quality system document. The effective period of the document is March 23, 2018 to October 7, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

March 30, 2018

Analysis of Drugs Manual

This document is an internal Drug Enforcement Administration quality system document. The effective period of this document is April 24, 2018 to September 9, 2019 and it is provided for informational purposes only. Any sensitive, privileged or otherwise protected information has been redacted, to include the redaction of some documents in their entirety. All redactions are clearly present in this document. Names of commercial manufacturers are provided for identification only, and inclusion does not imply endorsement by the Drug Enforcement Administration.

February 1, 2018

Cocaine/Fentanyl Combination in Pennsylvania

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) conducted an assessment of laboratory-analyzed drug seizures. Some seized cocaine exhibits were found to contain cocaine and fentanyl, as well as a combined cocaine and fentanyl presence in overdose death toxicology reporting. This analysis was conducted in response to reported increases in the co-occurrence of cocaine and fentanyl in other regions and subsequent inquiries regarding trends in Pennsylvania. 

February 1, 2018

Drug Presence in Pennsylvania 1999-2016

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) conducted a review of laboratory-analyzed drug seizures for the Commonwealth of Pennsylvania. The resulting analysis of this data formed the basis for estimating the level of drug presence in Pennsylvania and highlighted trends in drug availability between 1999 and 2016. 

February 1, 2018

Heroin Cocktail: An Analysis of Pennsylvania Laboratory Drug Seizure Data

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) Intelligence Program maintains situational awareness of drug availability, abuse, trafficking patterns, adulterants, concealment methods, etc., through analysis of law enforcement and public health information and data, as well as law enforcement source information. 

February 1, 2018

Deadly Contaminated Cocaine Widespread in Florida (2018)

A review of cocaine exhibits acquired by law enforcement authorities during operations across Florida and analyzed by forensic laboratories during the period from 2016 to 2017 revealed the widespread adulteration of cocaine with fentanyl and fentanyl-related substances. Fentanyl, a Schedule II opioid analgesic approximately 50 times more potent than heroin and 100 times more potent than morphine, carries a high risk of overdose and can be lethal at the 2-milligram range. Forensic chemists discovered fentanyl and fentanyl-related substances including acetyl fentanyl, carfentanil, Furanylfentanyl, and p-fluoroisobutyryl fentanyl in over 180 cocaine exhibits. Carfentanil, a synthetic opioid that is approximately 10,000 times more potent than morphine, was the most prevalent of the fentanyl-related substances found in Florida’s cocaine seizures. 

January 11, 2018

2017 Domestic Methamphetamine Threat Assessment Key Findings

The Domestic Methamphetamine Threat Assessment provides a comprehensive strategic assessment of the threat posed to the United States by the trafficking and use of methamphetamine. 

This report combines federal, state, and local law enforcement reporting; public health data; news reports; and intelligence from other government agencies to assess the methamphetamine threat to the United States. 

Methamphetamine is a Schedule II stimulant under the Controlled Substances Act (CSA). Methamphetamine is a synthetically-produced central nervous system stimulant that metabolizes slowly and has long-lasting effects. 

December 11, 2017

CRECER LIBRE DE DROGA GUÍA DE PREVENCIÓN PARA L S OS PADRES DE FAMILIA (2017)

Spanish version of publication, Growing Up Drug-Free:  A Parent's Guide to Prevention (April 2017).

 

November 28, 2017

Fentanyl Safety Recommendations for First Responders

The abuse of drugs containing fentanyl is killing Americans.  Misinformation and inconsistent recommendations regarding fentanyl have resulted in confusion in the first responder community.  This document provides scientific, evidence-based recommendations to protect first responders from exposure.

October 1, 2017

2015 Heroin Domestic Monitor Program

The Drug Enforcement Administration’s (DEA) Heroin Domestic Monitor Program (HDMP) is a retail-level heroin purchase program that provides data analysis about the geographic source of heroin, along with price, purity, adulterants, and diluents sold at the street-level in 27 U.S. cities. In 2015, a total of 823 qualified exhibits were purchased. Of those exhibits, 600 were classified as Mexican-origin heroin (267 Mexican-South American [MEX-SA], 252 Mexican-Black Tar [MEX/T], 49 Mexican-Brown Powder [MEX/BP], and 32 Mexican [MEX]); 178 heroin exhibits were classified as Inconclusive Origin-South American Processing Method (INC-SA); 42 were classified as South American (SA) heroin; and 3 were classified as Southwest Asian (SWA) heroin. During 2015, for the tenth consecutive year, no Southeast Asian (SEA) heroin exhibits were purchased through the HDMP. 

October 1, 2017

2017 National Drug Threat Assessment

The 2017 National Drug Threat Assessment (NDTA)1 is a comprehensive strategic assessment of the threat posed to the United States by domestic and international drug trafficking and the abuse of illicit drugs. The report combines federal, state, local and tribal law enforcement reporting; public health data; open source reporting; and intelligence from other government agencies to determine which substances and criminal organizations represent the greatest threat to the United States.

Over the past 10 years, the drug landscape in the United States has shifted, with the opioid threat (controlled prescription drugs, synthetic opioids, and heroin) reaching epidemic levels, impacting significant portions of the United States. While the current opioid crisis has deservedly garnered significant attention, the methamphetamine threat has remained prevalent; the cocaine threat appears to be rebounding; new psychoactive substances (NPS) continue to be a challenge; and the focus of marijuana enforcement efforts continues to evolve. Drug poisoning deaths are the leading cause of injury death in the United States; they are currently at their highest ever recorded level and, every year since 2011, have outnumbered deaths by firearms, motor vehicle crashes, suicide and homicide. In 2015, approximately 140 people died every day from drug poisoning (see Figure 1).

August 1, 2017

The 2015 Heroin Signature Program Report

The Drug Enforcement Administration’s (DEA) Heroin Signature Program (HSP) analyzes several hundred wholesale-level heroin samples each year to identify the geographic area—Mexico, South America (SA), Southwest Asia (SWA), or Southeast Asia (SEA)—where the samples were manufactured. 

DEA US Badge
United States Drug Enforcement Administration DEA.gov is an official site of the U.S. Department of Justice